Fig. 1

Clinical impact of circulating M-MDSCs on DLBCL patients. A Gating strategy of circulating M-MDSCs derived from healthy control’s or DLBCL patient’s PB using flow-cytometry analysis. B Percentage of circulating M-MDSCs among PB CD45⁺ cells in DLBCL patients with low, intermediate, or high-risk IPI scores. C Progression-free survival and D overall survival in DLBCL patients with low or high percentage of circulating M-MDSCs among PB CD45⁺ cells; the cut-off percentage of circulating M-MDSCs as 0.92% determined by ROC analysis and AUC. FSC, forward scatter; HR, hazard ratio; IPI, international prognostic index; M-MDSCs, monocytic myeloid-derived suppressor cells; mOS, median overall survival; mPFS, median progression-free survival; n, number; NR, non-reach; PB, peripheral blood